NCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but a strategic decision driven by changes in the treatment landscape and anticipated significant delays in patient enrollment. Show 5 more changesShow less
- Final enrollment: 1 participants, 4% of the 24 planned
- Eligibility criteria expanded, about 30 words
- Trial sites reduced: 5 → 1 locations
- Primary completion date changed from estimate of May 31, 2027 to Aug 17, 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Notable Eligibility criteria expanded, about 13 words
- Start date changed from estimate of Apr 30, 2026 to May 13, 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Notable Start date: Jan 31, 2026 to Apr 30, 2026v8
- Minor Study sites: 3 to 5v7
- Notable Start date: Dec 31, 2025 to Jan 31, 2026
- Study sites: 1 to 3
Show 4 earlier versionsHide 4 earlier versions
- Notable Start date: Oct 30, 2025 to Dec 31, 2025v5
- Notable Start date: Sep 15, 2025 to Oct 30, 2025
- Eligibility criteria expanded, about 24 words
- Secondary endpoints revised (5)
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Aug 1, 2025 to Sep 15, 2025
- Study sites: 0 to 1
- Notable Primary completion date: Sep 30, 2026 to May 31, 2027
- Start date: Jun 28, 2025 to Aug 1, 2025
- Study completion date: Mar 30, 2027 to Sep 26, 2027
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Adverse Events (AEs)
Timeframe: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)
Secondary (5)
Overall Response Rate (ORR)
Duration of response (DoR)
Progression-free survival (PFS)
Overall survival (OS)
Plasma pharmacokinetic profile of NMS-03305293 and possible identified metabolites (if appropriate) after oral administration
Arms and interventions
NMS-03305293 and TopotecanExperimental
NMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m\^2 with maximum dose of 4 mg.
Drugs: NMS-03305293, Topotecan
Sites
1 site in 1 country
- Penn Medicine - Perelman Center for Advanced MedicinePhiladelphia, Pennsylvania, United States